Eli Lilly’s big-earning ADHD med Strattera has succumbed to generics. Four drugmakers won FDA green lights for their copycats Tuesday, and the competitive pressure is expected to quickly tank the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback